Lectures by country and year [Top 2-10 countries] (Abbreviations: AU: Australia, BR: Brazil, CA: Canada, CN: China, DE: Germany, IT: Italy, JP: Japan, KR: South Korea, TW: Taiwan). by Ignacio García-Espona (21395335)

Subjects:

Lecturer ratios (women/men) by country and year [Top 10 countries] (Abbreviations: AU: Australia, BR: Brazil, CA: Canada, CN: China, DE: Germany, IT: Italy, JP: Japan, KR: South Ko... by Ignacio García-Espona (21395335)

Subjects:

Sample Data. by Ignacio García-Espona (21395335)

Subjects:

Variations in the prevalence of OASI in France between 2010 and 2021 according to the classification for episiotomy practices. by Raphaele Houlbracq (20558509)

Subjects:

Trends in the characteristics of women giving birth vaginally in France between 2010 and 2021. by Raphaele Houlbracq (20558509)

Subjects:

Variations in the prevalence of episiotomy in France between 2010 and 2021 according to the classification for episiotomy practices. by Raphaele Houlbracq (20558509)

Subjects:

Flow chart. by Raphaele Houlbracq (20558509)

Subjects:

pmed.1004501.t001 - Episiotomies and obstetric anal sphincter injuries following a restrictive episiotomy policy in France: An analysis of the 2010, 2016, and 2021 National Perinat... by Raphaele Houlbracq (20558509)

Subjects:

Table 2_Bibliometric analysis of global research on the clinical applications of aminoglycoside antibiotics: improving efficacy and decreasing risk.docx by Tengxiang Zhao (20749475)

“…Avoiding prolonged dosing cycles and refraining from using AGs in patients with the m.1555 A > G gene variant can significantly mitigate the risk of ototoxicity. Future studies should examine the pharmacokinetic and pharmacodynamic targets of AGs and assess the efficacy and safety of administration by inhalation to improve efficacy and decrease risk.…”

Table 1_Bibliometric analysis of global research on the clinical applications of aminoglycoside antibiotics: improving efficacy and decreasing risk.docx by Tengxiang Zhao (20749475)

“…Avoiding prolonged dosing cycles and refraining from using AGs in patients with the m.1555 A > G gene variant can significantly mitigate the risk of ototoxicity. Future studies should examine the pharmacokinetic and pharmacodynamic targets of AGs and assess the efficacy and safety of administration by inhalation to improve efficacy and decrease risk.…”

BT9 did not improve survival in the orthotopic xenograft model of D425 medulloblastoma. by Zahra Motahari (6814013)

Subjects:

The effect of MAGMAS inhibition on mitochondrial respiration and acidification rate in D425 cells. by Zahra Motahari (6814013)

Subjects:

PAM16 correlation with N-MYC. by Zahra Motahari (6814013)

Subjects:

MAGMAS inhibition on mitochondrial activity in medulloblastoma cells. by Zahra Motahari (6814013)

Subjects:

MAGMAS inhibition reduces DAOY cells migration. by Zahra Motahari (6814013)

Subjects:

MAGMAS inhibition induces medulloblastoma cell death. by Zahra Motahari (6814013)

Subjects:

BT9 reduces DAOY and D425 medulloblastoma cell invasion. by Zahra Motahari (6814013)

Subjects:

Expression of MAGMAS in medulloblastoma. by Zahra Motahari (6814013)

Subjects:

BT9 exhibits a dose- and time-dependent cytotoxic effect on medulloblastoma. by Zahra Motahari (6814013)

Subjects:

Biochemical data. by Abdallah Tageldein Mansour (21158819)

“…The colitic group showed a significant increase (P < 0.05) in C-reactive protein (CRP) and myeloperoxidase (MPO) and nitric oxide (NO) (35.60, 163.30 and 280 nmol/g tissue respectively) and higher expression (P < 0.05) <i>IL-17</i>, <i>TNF-α</i>, and <i>IL-1β</i> (increased up to 2.99, 4.36 and 4.90 respectively unlike PPE-NPsIII that recorded reduced levels of CRP, MPO and NO (8,96, 78.30 and 123 nmol/g tissue respectively) and much lower (P < 0.05) levels of IL-17, TNF-α, and IL-1β expression (decreased to 1.23, 1.69 and 1.64, respectively). …”